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Introduction
Mefenamic acid (MFA) product 
performance is highly dependant on 
particle size and can lead to variable 
efficacy. 
In this study, a structured development 
program was applied, developing a 
crystalline solid dispersion (CSD) 
formulation, retaining API properties 
and improving performance consistency 
compared to a commercial product.
Conclusion
Rheology guided process development was successful, but also highlights the limitations of this technique. 
The targeted immediate release profile for the CSD of MFA in Soluplus®-Sorbitol formulation has been met, whilst the stable 
crystalline form (I) of MFA has been retained and the consistency of drug release has been significantly improved. 
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HUB target product profile
Dose form Oral solid dose form
Dose 250 mg Mefenamic acid (MFA)
Release profile
• IR release profile, controlled via particle size
• Consistent performance
Formulation Crystalline solid dispersion (CSD)
Process HME – 3D print/ injection mould
Predictive 
approach
Rheology screening tool to predict HME process 
parameters
0
0.5
1
1.5
2
2.5
3
3.5
4
0 5 10 15 20 25 30 35 40
In
te
n
si
ty
2 θ [°]
0
20
40
60
80
100
120
0 10 20 30 40 50 60%
 la
b
el
 c
la
im
 M
FA
 r
el
e
as
ed
time (mins)
Figure 1: USP II dissolution test (pH 9) of 
250mg MFA capsules, Pharmavit Limited 
(PVL), Batch 4348: red dashed line 85% 
drug release.
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Figure 2: Complex viscosity versus 
angular frequency for Soluplus +15% 
w/w Sorbitol (SOL15) at 120°C (blue), 
130°C (orange) and 140°C (black).
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Figure 3: Storage (filled) and Loss (open) 
modulus versus angular frequency for 
SOL15 at 120°C (blue), 130°C (orange) 
and 140°C (black).
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Figure 5: 
HME process data. 
A) Die pressure, 
B) Torque, 
C) Rise in product 
temperature and 
D) Filament diameter 
versus screw speed: 
SOL15: black-140°C, 
orange-130°C; 
50MFA-SOL15: 
purple-125°C. 
Figure 6: HME 
extruded filaments: 
top 50MFA-SOL15, 
bottom SOL15.
Figure 4: 50% w/w 
MFA in SOL15SORB 
after rheology test
Predicted HME process 
temperature: 132°C
Dominating viscoelastic 
properties with angular 
frequency  : 
• viscous (G”) >140°C 
• elastic (G’) <130°C
Screening failed >20% w/w
Lowest HME process 
Temperature:
SOL15: 130°C
50MFA-SOL15: 125°C
Product temperature :
SOL15 130°C > 140°C
Die swell SOL15:
130°C > 140°C
Figure 9: Mechanical properties of 50MFA-
SOL15 and SOL15. extrudates: A) Flexural 
modulus, Strain at max stress, B) Max stress 
and Modulus of toughness (MoT).
Figure 7: XRPD data of extrudates: 
top 50MFA-SOL15, bottom SOL15.
Figure 8: 
SEM image of  50MFA-
SOL15 and SOL15
extrudates.
Figure 10: USP II dissolution test (pH 9) of 
250mg MFA capsules with 50MFA-SOL15 
extrudate. red dashed line 85% drug 
release.
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Table 1: HUB acid target product profile.
